In young adult gliomas, we identified enrichment of KRAS and CCND2 amplifications with potential targeted treatment options, whereas later-onset LGG showed higher rates of actionable EGFR amplification (Figure 7D). The gene discussed is KRAS; the disease is central nervous system cancer.